DRAPER, Utah, Aug. 13, 2024 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest health savings account (“HSA") custodian, today announced plans to release its second quarter of fiscal 2025 financial results following the close of regular stock market trading hours on Tuesday, September 3, 2024. Following the news release, HealthEquity management plans to host a conference call for investors on Tuesday, September 3, 2024, at 4:30 p.m. Eastern Time during which management will review the Company’s second quarter results.
HealthEquity Second Quarter Fiscal Year 2025 Results Conference Call | |
Date: | September 3, 2024 |
Time: | 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time |
Dial-In: | 1-833-630-1956 (US and Canada) 1-412-317-1837 (International) |
Conference ID: | HealthEquity |
Webcast: | ir.healthequity.com |
A replay of the conference call will be made available on the Company’s website at ir.healthequity.com.
The Company also announced that its management team plans to present and meet with investors at the following upcoming investor conferences:
2024 Wells Fargo Healthcare Conference | |
Location: | Encore Boston Harbor |
Date: | September 4, 2024 |
Time: | 2:15 p.m. Eastern Time |
Webcast: | none |
2024 RW Baird Global Healthcare Conference | |
Location: | InterContinental New York Barclay |
Date: | September 10, 2024 |
Time: | 2:35 p.m. Eastern Time |
Webcast: | none |
About HealthEquity
HealthEquity and its subsidiaries administer HSAs and various other consumer-directed benefits for over 16 million accounts, working in close partnership with employers, benefits advisors, and health and retirement plan providers who share our unwavering commitment to our mission of saving and improving lives by empowering healthcare consumers. Through cutting-edge solutions, innovation, and a relentless focus on improving health outcomes, we empower individuals to take control of their healthcare journey while ultimately enhancing their overall well-being. Learn more about our “Purple” service and approach at www.healthequity.com.
Forward-looking statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding our industry, business strategy, plans, goals and expectations concerning our markets and market position, product expansion, future operations, expenses and other results of operations, revenue, margins, profitability, acquisition synergies, future efficiencies, tax rates, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words “may,” “believes,” “intends,” “seeks,” “aims,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “will,” “future” and the negative of these or similar terms and phrases are intended to identify forward-looking statements in this press release.
Forward-looking statements reflect our current expectations regarding future events, results or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to be correct. Some of these expectations may be based upon assumptions, data or judgments that prove to be incorrect. Actual events, results and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, risks related to the following:
For a detailed discussion of these and other risk factors, please refer to the risks detailed in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the fiscal year ended January 31, 2024 and subsequent periodic and current reports. Past performance is not necessarily indicative of future results. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Investor Relations Contact:
Richard Putnam
801-727-1000
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$91.54 |
Daily Change: | 0.45 0.49 |
Daily Volume: | 920,155 |
Market Cap: | US$7.930B |
November 12, 2024 October 15, 2024 September 03, 2024 September 03, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB